Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression

Report Hive Market Research Released a New Research Report of 101 pages on Title " Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression "with detailed Analysis, Forecast and Strategies.

Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression

Summary

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.

The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.

The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.

Request Free Research Sample: https://www.reporthive.com/request-sample.php?id=904624

Scope

Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden
- What are the most important etiological risk factors and pathophysiological processes implicated in AD?
- What is the current treatment algorithm?
- How common are anxiety, depression, psychosis and insomnia in AD?
The AD pipeline is large and contains a very high proportion of first-in-class product innovation
- Which molecule types and molecular targets are most prominent across AD and its associated indications?
- What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
- Which first-in-class targets are most promising?
- How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
- How does first-in-class target diversity differ by stage of development and molecular target class?
The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products
- Which indications attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Table of Contents

Chapter One: Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

Browse Full Report: https://www.reporthive.com/details/frontier-pharma-alzheimer-s-disease-and-associated-indications-exceptional-level-of-first-in-class-innovation-within-ad-and-diverse-range-of-therapies-in-development-for-disorders-such-as-anxiety-and-depression

2 Executive Summary 6
2.1 Limited Treatment Options despite Large Market Opportunity 6
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline 6
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products 6

Key questions answered in the report

· What will the market size and the growth rate be in 2021?
· What are the key factors driving the Frontier Pharma: Alzheimer’s Disease and Associated Indications Market?
· What are the key market trends impacting the growth of the Frontier Pharma: Alzheimer’s Disease and Associated Indications Market?
· What are the challenges to market growth?
· Who are the key vendors in this market space?
· What are the market opportunities and threats faced by the vendors in the Frontier Pharma: Alzheimer’s Disease and Associated Indications Market?
· Trending factors influencing the market shares of the Americas, APAC, and EMEA?
· What are the key outcomes of the five forces analysis of the Frontier Pharma: Alzheimer’s Disease and Associated Indications Market?

We are a leading repository of market research reports and solutions catering to industries like Comm & Technology, Energy & Power, Food And Beverages, Automotive & Transportation, Healthcare & Life Science etc. This large collection of reports assists organizations in decision-making on aspects such as market entry strategies, market sizing, market share analysis, competitive analysis, product portfolio analysis and opportunity analysis among others. We also assist in determining the best suited and targeted report from our large repository of global reports, company-specific reports and country-level reports.

Mike Ross
Marketing Manager
mike.ross@reporthive.com
http://www.reporthive.com
Phone: +1 312-604-7084
Sainath Nagar, Vadgaon Sheri,
Pune, Maharashtra 411014

This release was published on openPR.